Description

Y-shapePEGNHSEster withsuperiorqualityspecificationof ≥95%Substitution.

Y-shapePEGNHS fromJenKemTechnologyisaSuccinimidylCarboxymethylEsterbranched2ARMPEG,reactivetowardstheaminogroupoflysine(s)onproteinsorotherBIOLOGics.AminePEGylationwithY-shapePEGNHScanbecompletedinlessthan1hratpH7-8.JenKemproprietaryY-shapePEGsaremoreselective,duetotheirstericallybulkystructure.PleasereviewtheapplicationnoteforthisproductforadditionalinstructionsforaminePEGylationwithY-NHS-40K.

JenKemTechnologyoffers Y-shapePEGNHS withMW40000,in1gand10gpackingsizes. JenKemTechnology providesrepackagingservicesforanadditionalfee,pleasecontactusifyourequireadifferentpackagesizethanourcatalogselection.

DifferentMWof Y-shapePEGNHS productsmaybeavailablebycustomsynthesis,pleaseemailus attech@jenkemusa.comfordetailsoncustomPEGs.

BulkPEGsandGMPgradePEGsaremade-to-order.Please contactus forbulkpricing.

ApplicationofY-NHS-40KforPEGylation:

DrugMoleculeorOtherEntityPEGylatedwithY-NHS-40K	References
Calciumphosphatenanoparticles	7
Cp40	4
DNAaptamer(SOMAmer)	2
G-CSF	15
Gentamicin	14
IFN-α2a	16
IFN-α2b	17
LIFreceptorantagoNIST(LA)	11
L-RNA(Spiegelmer)	5
L-RNA(Spiegelmer)	8
rhGH	18
TNF-α	9,10

ClickheretodownloadtheMSDS

References:

1.AlQahtani,A.D.,etal.,Productionof“biobetter”glucarpidasevariantstoimprovedrugdetoxificationandantibodydirectedenzymeprodrugtherapyforcancertreatment,EuropeanJournalofPharmaceuticalSciences,2019,127,P.79-91.

2.Haruta,K.,etal.,ANovelPEGylationMethodforImprovingthePharmacokineticPropertiesofAnti-Interleukin-17ARNAAptamers,Nucleicacidtherapeutics,2017,27(1):36-44.

3.Guo,L.,etal.,ApplicationInstructionsforY-NHS-40KforAminePEGylation,click link.

4.Masao,H.,etal.,ChemicallyModifiedInterleukin-6AptamerInhibitsDevelopmentofCollagen-InducedArthritisinCynomolgusMonkeys,NucleicAcidTherapeutics,2015.

5. Winship,A.L.,Interleukin-11altersplacentationandcausespreeclampsiafeaturesinmice,ProcNatlAcadSciUSA.,2015,112(52):15928-33.

6. Risitano,A.M.,etal., PeptideinhibitorsofC3activationasanovelstrategyofcomplementinhibitionforthetreatmentofparoxysmalnocturnalhemoglobinuria, BloodMar,2014,123(13)2094-2101.

7.Roccaro,Aldo M.etal., SDF-1InhibitionTargetstheBoneMarrowNicheforCancerTherapy, CellReports,2014,9(1),p:118–128.

8. Stefan,N.,etal.,NovelProdrug-LikeFusionToxinwithProtease-SensitiveBioorthogonalPEGylationforTumorTargeting,Bioconjugatechemistry, 2014,25.12:2144-2156.

9.Ashokan,A.,etal.,Multifunctionalcalciumphosphatenano-contrastagentforcombinednuclear,magneticandnear-infraredin vivoimaging.Biomaterials,2013,34(29):p.7143-7157.

10.Khan,M.A.,etal., Targetingcomplementcomponent5apromotesvascularintegrityandlimitsairwayremodeling,PNAS,2013,110(15)p:6061-6066.

11. Dai,C.Y., etal.,PreparationandevaluationofanewreleasablePEGylatedtumornecrosisfactor-α(TNF-α)conjugatefortherapeuticapplication,ScienceChinaLifeSciences,2013,56.1:51-58.

12.Dai, C.Y.,etal., LinkagewithcathepsinB-sensitivedipeptidepromotestheinvitroandinvivoanticanceractivityofPEGylatedtumornecrosisfactor-alpha(TNF-α)againstmurinefibrosarcoma, ScienceChinaLifeSci,2011,54(2):128–138.

13. Menkhorst,E.,etal.,VaginallyAdministeredPEGylatedLIFAntagonistBlockedEmbryoImplantationandEliminatedNonTargetEffectsonBoneinMice,PLoSONE, 2011,6(5)e19665.

14. Cai,Y.,etal.,Separationofexenatideanaloguemono-PEGylatedwith40kDApolyethyleneglycolbycationexchangechromatography,JournalofChromatographyA,2011,1218:39,P.6953-6960.

15. Wang,Y-J.,etal.,PEGylationmarkedlyenhancestheinvivopotencyofrecombinanthumannon-glycosylatederythropoietin:Acomparisonwithglycosylatederythropoietin,JournalofControlledRelease, 2010,145:3,p. 306-313.

16.Marcus,Y.,etal.,TurningLow-Molecular-WeightDrugsintoProlongedActingProdrugsbyReversIBLePegylation:AStudywithGentamicin, JournalofMedicinalChemistry,2008,51(14),4300-4305.

17.Wang,S.,etal.,Y-typepolyethyleneglycolmodifiedG-CSFandpreparationmethodandusethereof.PatentCN200780051378,2007.

18.Zhou,W.,etal.,Interferonalpha2amodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050541,2007.

19.Zhou,W.,etal.,Interferonalpha2bmodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050542,2007.

20.Zhou,W.,etal.,Double-strandedpolyethyleneglycolmodifiedgrowthhormone,preparationmethodandapplicationthereof.PatentCN200880009718,2008.

Foundedin2001byexpertsinPEGsynthesisandPEGylation,JenKemTechnologyspecializesexclusivelyinthedevelopmentandmanufacturingofhighqualitypolyethyleneglycol(PEG)productsandderivatives,andrelatedcustomsynthesisandPEGylationservices.JenKemTechnologyisISO9001andISO13485certified,andadherestoICHQ7AguidelinesforGMPmanufacture.TheproductionofJenKem®PEGsisback-integratedtoin-housepolymerizationfromethyleneoxide,enablingfaciletraceABIlityforregulatedcustomers.JenKemTechnologycaterstothePEGylationneedsofthepharmaceutical,biotechnology,medicaldeviceanddiagnostics,andemergingchemicalspecialtymarkets,fromlaboratoryscalethroughlargecommercialscale.

JenKem用于胺聚乙二醇化的活化PEGJenKem Technology生产具有NHS和羧基官能度，高纯度和低多分散性的用于胺PEG化的高质量活化PEG。在结构上，JenKem Technology提供胺反应性线性PEG，Y形PEG，U形PEG，多臂PEG和单分散PEG。JenKem Technology专有的Y形支化PEG衍生物的空间庞大结构，由两个连接在具有活性NHS基团的中心核上的线性甲氧基PEG链组成，可能有助于减少蛋白质分子的附着位点数量。具有稳定连接子的PEG NHS酯：MPEG-SCM，MPEG-SPA，MPEG-SBA，MPEG-SHA，MPEG-SGA，MPEG-SSA，SCM-PEG-SCM，Y-PEG-NHS，MPEG2-LYS-PEG-NHS ，GLUC-PEG-NHS，GALA-PEG-NHS带有碳酸酯连接基的PEG产品：MPEG-SC，MPEG-NPC具有可裂解NHS酯连接基的可降解PEG：MPEG-SS，SS-PEG-SS和MPEG-SGPEG羧基：Y-PEG-COOH，MPEG-CM，MPEG-PA，MPEG5-PA，MPEG6-PA，MPEG-BA，MPEG-HA –比NHS PEG稳定。使用JenKem®Y-PEG-NHS进行蛋白质PEG化的示意图分子量，支链和官能团未在我们的在线目录中列出的胺PEG化产品可通过定制合成以及PEG化服务获得。JenKem Technology通过定制合成提供GMP级PEG衍生物和批量订单，从而有机会满足客户的特殊质量要求。根据ICH Q7A准则，JenKem Technology能够根据ISO 9001和ISO 13485认证的质量管理体系，以200g至40kg或更大的批次开发和合成各种GMP PEG衍生物。2020年，JenKem Technology将过渡为使用  高纯度（> 99％）mPEG  原料生产GMP级甲氧基PEG衍生物。